Divi's Laboratories — Q3 FY26
Divi's Laboratories reported Q3 FY26 PAT of ₹583 crore, broadly flat YoY, impacted by a one-time exceptional charge of ₹74 crore due to labor code changes.
bullish
medium
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
58%Questions answered3Evaded / deflected12Questions audited
Partial answer
High priority
Update on GLP-1 capacity buildup and pilot plant commercialization.
Asked by Surya Narayan Patra, PhillipCapital
Acknowledged progress but refused to quantify capacity, citing confidentiality.
no capacity number givencited confidentiality
Read the exchange
Question
So that we have been saying that we have already commercialized one pilot plant in the earlier this thing that we had mentioned. So what is the capacity buildup that we are doing? Can you give some update on that front further?
Kiran S. Divi, Whole-Time Director and CEO
So on GLP-1s, okay, we have already like I explained last time, we have already completed construction of a pilot plant. We have also completed one of our commercial buildings, which has several large-scale SPPSs, which is basically designed based on one of our customer's requirements. So I'm not at the liberty to speak about capacity created, but the validations are going on as we speak right now because pilot work is done. Now it's moving towards validations.
Evasive
High priority
Are the three dedicated CS facilities related to peptides?
Asked by Surya Narayan Patra, PhillipCapital
Declined to answer directly, gave a non-specific response.
refused to confirmvague answer
Read the exchange
Question
The three dedicated custom synthesis facilities what we have got the contracts for and which are likely to see the commercialization starting from the fourth quarter of FY27. So any of those are relating to peptides?
Kiran S. Divi, Whole-Time Director and CEO
I cannot comment on that, but what I can tell you is it's a mixture of everything. It's also in chemistry. There are several projects which are involved in it.
Partial answer
Medium priority
Capacity utilization and progress on contrast media opportunities.
Asked by Surya Narayan Patra, PhillipCapital
Provided overall capacity utilization but not specific to contrast media.
no specific contrast media capacity given
Read the exchange
Question
Again, about the capacity positioning that we would be having about the contrast media and all that. So what is the capacity that we would be having or at what utilization that we would be operating at? Any progress on the kind of newer opportunities that we have talked about?
Kiran S. Divi, Whole-Time Director and CEO
So I mean, just to generalize because you spoke about several segments, okay, capacity utilization, we are about 70%-80% of capacity utilization right now. Depending on the month, and sometimes you're at 80%-85%, sometimes you're at 70%, depends on when the shipments would be happening.
Answered
High priority
Clarification on CS molecules moving to commercial volumes and timeline.
Asked by Tushar Manudhane, Motilal Oswal Financial Services
Clearly explained the process and timeline without evasion.
Read the exchange
Question
With respect to a comment in your opening remarks about few molecules going to commercial volumes over the next one year within CS segment... broadly to understand whether here is it more like the inventory buildup by the innovator... if you could throw some light on this aspect?
Kiran S. Divi, Whole-Time Director and CEO
All I can say is once the validations are completed and some are already completed, we are waiting for all regulatory approvals, after which the volumes would be discussed for commercialization. So that is what we're expecting to happen in the next one year.
Answered
Medium priority
Hedging policy for export exposure.
Asked by Tushar Manudhane, Motilal Oswal Financial Services
Clearly stated no hedging and that evaluation is ongoing.
Read the exchange
Question
On the hedging policy, if you could throw light like how much of the business exposure we hedge or we don't hedge any of the exports, if you could throw some light on that as well?
Nilima Divi, Whole-Time Director Commercial
We are not hedging. We are evaluating at this point based on the overall scenario in the market.
Answered
High priority
Why limited growth in generic API despite stable raw materials?
Asked by Tushar Manudhane, Motilal Oswal Financial Services
Explained that volume growth is offset by pricing pressure, directly addressing the question.
Read the exchange
Question
What is stopping us from the growth in the generic space?
Nilima Divi, Whole-Time Director Commercial
See, the generic space, the pricing pressures are still continuing. We haven't mentioned that the pricing have eased. We did mention that the pricing pressures are still continuing. But if we look at generics, we need to see one is the value and another is the volume. As a volume, we have had a good growth. But it's just that because of the pricing pressures, value-wise, it doesn't reflect in that manner.
Partial answer
High priority
Drivers of sharp gross margin improvement in Q3.
Asked by Kunal Dhamesha, Macquarie
Attributed to product mix but did not quantify or explain QoQ change despite similar mix.
no specific margin breakdowndeferred to nine-month view
Read the exchange
Question
There is a sharp improvement on both year-over-year as well as quarter-over-quarter basis in quarter three. If you could highlight the drivers of this improvement, that would be helpful.
Nilima Divi, Whole-Time Director Commercial
I would say it's mainly based on the product mix. As you can see, the CS has improved in the nine-month period as compared to the previous nine months. So it's mainly to do with the product mix rather than anything else.
Declined
High priority
Proportion of commercializing molecules that are already approved vs new.
Asked by Kunal Dhamesha, Macquarie
Refused to answer even at aggregate level, citing confidentiality.
cited confidentialityrefused to give aggregate
Read the exchange
Question
The molecules that we are believing would get commercialized over the next one year, what proportion of these molecules would be already approved for the innovators, and what proportion would get first-time approval?
Kiran S. Divi, Whole-Time Director and CEO
I'm sorry. I cannot answer this question because we are bound by CDA. I cannot disclose their plans and at what stages any of our customers are.
Answered
High priority
Timeline for commissioning of dedicated CapEx announced in 2024.
Asked by Neha Manpuria, BofA
Provided a clear timeline for commercialization.
Read the exchange
Question
On the dedicated CapEx that we had announced in 2024. When should we expect commissioning of that capacity and probably inspections or whatever regulatory approvals are required?
Kiran S. Divi, Whole-Time Director and CEO
By 2027, we should start seeing commercialization post our customers they start approving the product.
Partial answer
Medium priority
Impact of China's export rebate withdrawal on generic API portfolio.
Asked by Neha Manpuria, BofA
Clarified it's about procurement, not APIs, but did not quantify impact on portfolio.
corrected the premiseno percentage impact given
Read the exchange
Question
You mentioned about China's withdrawal of export rebates, putting pressure on certain generic APIs. Could you provide us some color in terms of what we are seeing here, what percentage of our portfolio is getting impacted?
Nilima Divi, Whole-Time Director Commercial
I didn't mention that with respect to the APIs. I said with respect to procurement of materials. So the withdrawal of export tax rebates has taken place and will be from April 1st. We are wary of the situation... we have increased our domestic supplier base to 78% of the procurement.
Evasive
Medium priority
Will the dedicated peptide building be sufficient for 4-5 years?
Asked by Vivek Agarwal, Citi
Did not answer whether capacity is sufficient; deferred to future demand and confidentiality.
no forward guidancecited confidentiality
Read the exchange
Question
You highlighted that you have completed construction of a dedicated building block for peptides that include various SPPS reactors. Just want to understand, will that be good enough to cater the customer demand for next 4-5 years, or is there any possibility that you may need to expand the capacities?
Kiran S. Divi, Whole-Time Director and CEO
So as and when we have demand, we will keep increasing capacity or building new blocks whenever the demand and question arises. For this customer, what we have dedicated, it is based on what his requirement and his designs are. I'm not at any other liberty to discuss on that.
Answered
High priority
Growth outlook for next 12 months given key product going generic.
Asked by Shyam Srinivasan, Goldman Sachs
Clearly stated no disruption and reaffirmed double-digit growth trajectory.
Read the exchange
Question
Given that one of our key products, top products, probably, which is in late lifecycle bucket, probably is going more generic this year, how should we look at next 12 months? Maybe even fiscal 2027, are there enough other things in the pipeline for us to mitigate?
Kiran S. Divi, Whole-Time Director and CEO
We do not see any; we do not foresee any disruption because, and it's in line with whatever our double-digit growth that we keep talking about. ... We always have a nice, decent balance of equilibrium while our growth trajectory is actually happening at the double-digit.